OmniAb (OABI) Current Assets (2021 - 2026)
OmniAb (OABI) posted quarterly Current Assets of $65.1 million for Q1 2026, up 21.55% year-over-year from $53.6 million in Q1 2025, and little changed quarter-over-quarter from $65.3 million in Q4 2025.
OmniAb (OABI) Current Assets (2021 - 2026) Analysis & Trends
OmniAb (OABI) has reported Current Assets for 6 consecutive years, with $65.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 21.55% year-over-year to $65.1 million; the TTM figure through Mar 2026 stood at $65.1 million (up 21.55% YoY), while the FY2025 annual figure was $65.3 million, down 4.1% from the prior year.
- Current Assets held at $65.1 million in Q1 2026 per OABI's latest filing, from $65.3 million in the prior quarter.
- Across five years, Current Assets topped out at $125.0 million in Q4 2022 and bottomed at $423868.0 in Q3 2022.
- Historically, Current Assets has averaged $67.2 million across 5 years, with a median of $66.6 million in 2024.
- Annual changes were most pronounced in 2022 — Current Assets plunged 65.88% — and 2023, when it surged 25107.85%.
- OmniAb's Current Assets stood at $125.0 million in 2022, then dropped by 24.05% to $94.9 million in 2023, then dropped by 28.2% to $68.1 million in 2024, then declined by 4.1% to $65.3 million in 2025, then slipped by 0.33% to $65.1 million in 2026.
- Business Quant data shows OABI's Current Assets at $65.1 million in Q1 2026, $65.3 million in Q4 2025, and $66.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn | 66.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 66.01 Mn |
| Mar 31, 2026 | 65.13 Mn |
| Dec 31, 2025 | 65.34 Mn |
| Sep 30, 2025 | 66.35 Mn |
| Jun 30, 2025 | 47.62 Mn |
| Mar 31, 2025 | 53.58 Mn |
| Dec 31, 2024 | 68.14 Mn |
| Sep 30, 2024 | 66.61 Mn |
| Jun 30, 2024 | 67.30 Mn |
| Mar 31, 2024 | 76.72 Mn |
| Dec 31, 2023 | 94.90 Mn |
| Sep 30, 2023 | 106.85 Mn |
| Jun 30, 2023 | 115.94 Mn |
| Mar 31, 2023 | 121.08 Mn |
| Dec 31, 2022 | 124.95 Mn |
| Sep 30, 2022 | 423,868.00 |
| Jun 30, 2022 | 692,011.00 |
| Mar 31, 2022 | 1.10 Mn |
| Dec 31, 2021 | 22.54 Mn |
| Sep 30, 2021 | 1.24 Mn |